Related Experiment Video
Updated: Jul 8, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
[A meta-analysis of the efficacy and safety of the anti-obesity agent Rimonabant]
Robin Christensen1, Pernelle Kruse Kristensen, Else Marie Bartels
1Frederiksberg Hospital, Parker Instituttet, Københavns Universitet, Det Biovidenskabelige Fakultet, Institut for Human Ernaering, Frederiksberg C.
Abstract:
A meta-analysis of all randomised controlled trials examining the efficacy and safety of the anti-obesity agent Rimonabant (Acomplia, 20 mg/d) found an efficacy of 4.7 kg (4.1-5.3) more weight loss after one year compared to placebo. Rimonabant increased the risk of adverse events, including depressive episodes and anxiety, despite depressive symptoms being an exclusion criterion in these trials. This, combined with an increased risk of suicidality during Rimonabant treatment, warrants increased awareness from prescribing physicians.
More Related Videos
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Antidepressant Drugs: MAOIs and Other Agents
Obesity
Drug Dosing: Obese Patients

